Advertisement

Other Skin Cancers

Fibrohistiocytic Skin Cancers and Extramammary Paget's Disease
  • Thomas StaskoEmail author
  • Sarah Grummer
Chapter
  • 855 Downloads

Core Messages

  • Dermatofibrosarcoma protuberans is a rare malignancy of intermediate aggressiveness which usually presents as an asymptomatic, slowly enlarging, indurated violaceous to flesh-colored plaque. Subclinical histologic extension consisting of tentacle-like projections between subcutaneous shelf-like tumor masses makes complete excision, even with wide margins, difficult. Mohs surgery appears to offer the best chance for complete excision. Inhibition of platelet-derived growth factor receptors with imatinib may reduce tumor size in metastatic or unresectable tumors.

  • Atypical fibroxanthoma is a spindle cell tumor most commonly found on actinically damaged skin, primarily the head and neck, of elderly Caucasians with a small potential for metastasis. It is characterized by spindle cells, bizarre multinucleated giant cells, xanthomatous cells and atypical mitoses. Complete excision, often with Mohs surgery, is the usual treatment.

  • Most tumors formerly diagnosed as malignant fibrous histiocytoma have now been reclassi-fied as non-sarcomatous malignancies. The remaining tumors, which tend to have a very aggressive course, are now best termed undif-ferentiated pleomorphic sarcomas.

  • Extramammary Paget's Disease is a rare cutaneous adenocarcinoma occurring on apocrine glandbearing skin in which the initial diagnosis if often delayed because of its clinical resemblance chronic conditions such as inter-trigo or contact dermatitis. Because of an association with internal malignancies, a through work-up for other cancers is necessary.

Keywords

Malignant Fibrous Histiocytoma Wide Local Excision Seborrheic Dermatitis Spindle Cell Tumor Soft Tissue Malignancy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Gloster HM Jr (1996) Dermatofibrosarcoma protuberans. J Am Acad Dermatol 35(3 Pt 1):355–374; quiz 375–6PubMedCrossRefGoogle Scholar
  2. 2.
    Ah-Weng A et al (2002) Dermatofibrosarcoma protuberans treated by micrographic surgery. Br J Cancer 87(12):1386–1389PubMedCrossRefGoogle Scholar
  3. 3.
    Young CR III, Albertini MJ (2003) Atrophic dermatofibrosar-coma protuberans: case report, review, and proposed molecular mechanisms. J Am Acad Dermatol 49(4):761–764PubMedCrossRefGoogle Scholar
  4. 4.
    Davis DA, Sanchez RL (1998) Atrophic and plaquelike der-matofibrosarcoma protuberans. Am J Dermatopathol 20(5):498–501PubMedCrossRefGoogle Scholar
  5. 5.
    Nouri K et al (2002) Mohs micrographic surgery for dermatofi-brosarcoma protuberans: University of Miami and NYU experience. Dermatol Surg 28(11):1060–1064; discussion 1064PubMedCrossRefGoogle Scholar
  6. 6.
    Haycox CL et al (1997) Dermatofibrosarcoma protuberans (DFSP): growth characteristics based on tumor modeling and a review of cases treated with Mohs micrographic surgery. Ann Plast Surg 38(3):246–251PubMedCrossRefGoogle Scholar
  7. 7.
    Kimmel Z et al (2007) Peripheral excision margins for der-matofibrosarcoma protuberans: a meta-analysis of spatial data. Ann Surg Oncol 14(7):2113–2120PubMedCrossRefGoogle Scholar
  8. 8.
    Ratner D et al (1997) Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans. Results of a multiinstitutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol 37(4):600–613CrossRefGoogle Scholar
  9. 9.
    Parker TL, Zitelli JA (1995) Surgical margins for excision of dermatofibrosarcoma protuberans. J Am Acad Dermatol 32(2 Pt 1):233–236PubMedCrossRefGoogle Scholar
  10. 10.
    Haycox CL et al (1997) Immunohistochemical characterization of dermatofibrosarcoma protuberans with practical applications for diagnosis and treatment. J Am Acad Dermatol 37(3 Pt 1):438–444PubMedCrossRefGoogle Scholar
  11. 11.
    Jimenez FJ et al (1994) Immunohistochemical margin control applied to Mohs micrographic surgical excision of der-matofibrosarcoma protuberans. J Dermatol Surg Oncol 20(10):687–689PubMedGoogle Scholar
  12. 12.
    Breuninger H, Schaumburg-Lever G (1988) Control of exci-sional margins by conventional histopathological techniques in the treatment of skin tumours. An alternative to Mohs' technique. J Pathol 154(2):167–171PubMedCrossRefGoogle Scholar
  13. 13.
    Breuninger H, Thaller A, Schippert W (1994) [Subclinical spread of dermatofibrosarcoma protuberans and resulting treatment modalities]. Hautarzt 45(8):541–545PubMedCrossRefGoogle Scholar
  14. 14.
    McArthur GA (2007) Molecular targeting of dermatofibro-sarcoma protuberans: a new approach to a surgical disease. J Natl Compr Canc Netw 5(5):557–562PubMedGoogle Scholar
  15. 15.
    Wright TI, Petersen JE (2007) Treatment of recurrent der-matofibrosarcoma protuberans with imatinib mesylate, followed by Mohs micrographic surgery. Dermatol Surg 33(6):741–744PubMedCrossRefGoogle Scholar
  16. 16.
    Stadler FJ, Scott GA, Brown MD (1998) Malignant fibrous tumors. Semin Cutan Med Surg 17(2):141–152PubMedCrossRefGoogle Scholar
  17. 17.
    Giuffrida TJ, Kligora CJ, Goldstein GD (2004) Localized cutaneous metastases from an atypical fibroxanthoma. Dermatol Surg 30(12 Pt 2):1561–1564PubMedCrossRefGoogle Scholar
  18. 18.
    Seavolt M, McCall M (2006) Atypical fibroxanthoma: review of the literature and summary of 13 patients treated with mohs micrographic surgery. Dermatol Surg 32(3):435–441; discussion 439–41PubMedCrossRefGoogle Scholar
  19. 19.
    Sakamoto A et al (2001) H-, K-, and N-ras gene mutation in atypical fibroxanthoma and malignant fibrous histiocytoma. Hum Pathol 32(11):1225–1231PubMedCrossRefGoogle Scholar
  20. 20.
    DeiTos AP et al (1994) Ultraviolet-induced p53 mutations in atypical fibroxanthoma. Am J Pathol 145(1):11–17Google Scholar
  21. 21.
    Tos AP (2006) Classification of pleomorphic sarcomas: where are we now? Histopathology 48(1):51–62CrossRefGoogle Scholar
  22. 22.
    Hultgren TL, DiMaio DJ (2007) Immunohistochemical staining of CD10 in atypical fibroxanthomas. J Cutan Pathol 34(5):415–419PubMedCrossRefGoogle Scholar
  23. 23.
    Davis JL et al (1997) A comparison of Mohs micrographic surgery and wide excision for the treatment of atypical fibroxanthoma. Dermatol Surg 23(2):105–110PubMedCrossRefGoogle Scholar
  24. 24.
    Helwig EB, May D (1986) Atypical fibroxanthoma of the skin with metastasis. Cancer 57(2):368–376PubMedCrossRefGoogle Scholar
  25. 25.
    Jacobs DS, Edwards WD, Ye RC (1975) Metastatic atypical fibroxanthoma of skin. Cancer 35(2):457–463PubMedCrossRefGoogle Scholar
  26. 26.
    Limmer BL, Clark DP (1997) Cutaneous micrographic surgery for atypical fibroxanthoma. Dermatol Surg 23(7):553–557; discussion 557–8PubMedCrossRefGoogle Scholar
  27. 27.
    Huether MJ, Zitelli JA, Brodland DG (2001) Mohs micro-graphic surgery for the treatment of spindle cell tumors of the skin. J Am Acad Dermatol 44(4):656–659PubMedCrossRefGoogle Scholar
  28. 28.
    Nouri K, Rivas MP (2004) A primer of Mohs micrographic surgery: uncommon indications. Skinmed 3(5):259–265PubMedCrossRefGoogle Scholar
  29. 29.
    Fletcher CDM, Unni KK, Mertens F (2002) Pathology and genetics of tumors of soft tissue and bone. WHO classification of tumours. ARC Press, LyonGoogle Scholar
  30. 30.
    Fletcher CD (1992) Pleomorphic malignant fibrous histiocy-toma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am J Surg Pathol 16(3):213–228PubMedCrossRefGoogle Scholar
  31. 31.
    Mentzel T et al (1996) Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. Am J Surg Pathol 20(4):391–405Google Scholar
  32. 32.
    Fletcher CD et al (2001) Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. J Clin Oncol 19(12):3045–3050PubMedGoogle Scholar
  33. 33.
    Coindre JM et al (2004) Inflammatory malignant fibrous his-tiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity. J Pathol 203(3):822–830PubMedCrossRefGoogle Scholar
  34. 34.
    Shepherd V, Davidson EJ, Davies-Humphreys J (2005) Extramammary Paget's disease. BJOG 112(3):273–279PubMedCrossRefGoogle Scholar
  35. 35.
    Coldiron BM, Goldsmith BA, Robinson JK (1991) Surgical treatment of extramammary Paget's disease. A report of six cases and a reexamination of Mohs micrographic surgery compared with conventional surgical excision. Cancer 67(4):933–938PubMedCrossRefGoogle Scholar
  36. 36.
    Zollo JD, Zeitouni NC (2000) The Roswell Park Cancer Institute experience with extramammary Paget's disease. Br J Dermatol 142(1):59–65PubMedCrossRefGoogle Scholar
  37. 37.
    O'Connor WJ et al (2003) Comparison of mohs micro-graphic surgery and wide excision for extramammary Paget's disease. Dermatol Surg 29(7):723–727PubMedCrossRefGoogle Scholar
  38. 38.
    Cohen PR et al (2006) Treatment of extramammary Paget disease with topical imiquimod cream: case report and literature review. South Med J 99(4):396–402PubMedCrossRefGoogle Scholar
  39. 39.
    Gregori CA, Smith CI, Breen JL (1978) Extramammary Paget's disease. Clin Obstet Gynecol 21(4):1107–1115PubMedCrossRefGoogle Scholar
  40. 40.
    Chanda JJ (1985) Extramammary Paget's disease: prognosis and relationship to internal malignancy. J Am Acad Dermatol 13(6):1009–1014PubMedCrossRefGoogle Scholar
  41. 41.
    Kanitakis J (2007) Mammary and extramammary Paget's disease. J Eur Acad Dermatol Venereol 21(5):581–590PubMedGoogle Scholar
  42. 42.
    Marchesa P et al (1997) Long-term outcome of patients with perianal Paget's disease. Ann Surg Oncol 4(6):475–480PubMedCrossRefGoogle Scholar
  43. 43.
    Lundquist K, Kohler S, Rouse RV (1999) Intraepidermal cytokeratin 7 expression is not restricted to Paget cells but is also seen in Toker cells and Merkel cells. Am J Surg Pathol 23(2):212–219PubMedCrossRefGoogle Scholar
  44. 44.
    Smith KJ et al (1997) Cytokeratin 7 staining in mammary and extramammary Paget's disease. Mod Pathol 10(11):1069–1074PubMedGoogle Scholar
  45. 45.
    Hendi A, Brodland DG, Zitelli JA (2004) Extramammary Paget's disease: surgical treatment with Mohs micrographic surgery. J Am Acad Dermatol 51(5):767–773PubMedCrossRefGoogle Scholar
  46. 46.
    Thomas CJ, Wood GC, Marks VJ (2007) Mohs micro-graphic surgery in the treatment of rare aggressive cutaneous tumors: the Geisinger experience. Dermatol Surg 33(3):333–339PubMedCrossRefGoogle Scholar
  47. 47.
    Louis-Sylvestre C, Haddad B, Paniel BJ (2001) Paget's disease of the vulva: results of different conservative treatments. Eur J Obstet Gynecol Reprod Biol 99(2):253–255PubMedCrossRefGoogle Scholar
  48. 48.
    Watanabe Y et al (2002) Low-dose mitomycin C, etoposide, and cisplatin for invasive vulvar Paget's disease. Int J Gynecol Cancer 12(3):304–307PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  1. 1.Vanderbilt UniversityNashvilleUSA
  2. 2.The Vanderbilt ClinicNashvilleUSA

Personalised recommendations